Plain-English translation of NCT06341205 on ClinicalTrials.gov ↗ ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a smarter way to treat membranous nephropathy, an autoimmune kidney disease. Instead of giving all patients the same dose of rituximab, the trial uses artificial intelligence to predict how much medication each person's body will actually keep and use. Based on that prediction, some patients will receive a standard dose while others will receive higher doses to make sure the medication works better.
Right now, about 40% of patients don't respond well to the standard rituximab treatment for this kidney disease. Researchers discovered that the medication can be lost in urine, meaning patients don't get enough of it in their bloodstream to work effectively. This trial aims to solve that problem by personalizing doses based on each person's predicted medication levels.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either standard rituximab doses or personalized doses based on an AI algorithm. The medication is given as infusions into your vein on specific days. If you're in the personalized group, you may receive 2, 3, or 4 infusions depending on what the algorithm predicts about your medication levels. Throughout the study, you'll have blood tests to check your kidney function, protein levels, and medication levels in your bloodstream. The study follows patients for several months to see who achieves remission of their kidney disease.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
France